Skip to main content
Premium Trial:

Request an Annual Quote

Team GenomeWeb

Premium

Front row, L to R: Marian Moser Jones, editor, BioArray News; Harry Greenwald, COO and publisher; Erika Rullman, BioInform and BioArray circulation sales and marketing; Marina Gulko, circulation assistant

Second row, L to R: Paul Towlen, director of business development; Sofia Minchenko, accountant; Meredith Salisbury, managing editor, Genome Technology; Adrienne Burke, editorial director; Miriam Smith, circulation manager; Karen Richmond, administrator

Third row, L to R: Chris Rockaway, senior advertising account manager; Bernadette Toner, editor, BioInform; Aaron Sender, senior editor, Genome Technology; Gwen Libsohn, production manager; John MacNeil, reporter, GenomeWeb.com

Back row, L to R: Yaron Varsano, senior advertising account manager; Alison McCook, editorial intern; Dennis Waters, CEO and chairman; Kirell Lakhman, editor, GenomeWeb.com. Ken Howard, senior reporter and West Coast correspondent, GenomeWeb.com.

Not pictured: Jennifer Friedlin, European correspondent, GenomeWeb.com; Nat Goodman, the IT Guy; Brad Stenger, Active Site columnist; and the entire art and production team which was at work laying out this issue while the rest of us were clowning around in front of the camera.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.